IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples